SCHEMBL19555015

SCHEMBL19555015

Cc1cc(-c2ccc(F)cc2)nnc1C#N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GABRG2 P18507 1/20 0.43
▸ GABRB3 P28472 1/20 0.43
▸ GABRA5 P31644 1/20 0.43
▸ GABRA3 P34903 1/20 0.43
▸ MEN1 O00255 4/20 0.43
▸ KMT2A Q03164 4/20 0.43
▸ ERBB2 P04626 1/20 0.42
▸ ALDH1A1 P00352 5/20 0.40
▸ HPGD P15428 4/20 0.40
▸ KDM4E B2RXH2 3/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ SQOR Q9Y6N5 4/20 0.40
▸ MAPT P10636 3/20 0.39
▸ PKM P14618 2/20 0.39
▸ ATM Q13315 2/20 0.39
▸ GLA P06280 1/20 0.39
▸ GAA P10253 1/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ MAOB P27338 1/20 0.39
▸ CASP3 P42574 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15253770 0.83 L3MBTL1 (0.51) GABRG2GABRB3GABRA5GABRA3MEN1
SCHEMBL19555067 0.83 GABRG2 (0.50) GABRG2GABRB3GABRA5GABRA3MEN1
SCHEMBL29779696 0.74 NPC1 (0.41) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL19554988 0.74 RAB9A (0.43) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL19554487 0.74 NPC1 (0.41) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL5814391 0.72 ADORA2A (0.54) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL19554539 0.71 MAOB (0.48) MEN1KMT2AALDH1A1HPGDKDM4E
SCHEMBL19554661 0.70 NPC1 (0.39) MEN1KMT2AALDH1A1HPGDKDM4E
Hydrochloric Acid SCHEMBL28814964 0.70 OGG1 (0.46) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL19554643 0.68 ALDH1A1 (0.38) GABRG2GABRB3GABRA5GABRA3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11878979-B2 Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2024-01-23 — — US disclosed
CN-109311902-B Substituted imidazo [1,2-b ] pyridazines, imidazo [1,5-b ] pyridazines, related compounds, and uses thereof BIAL研发投资股份有限公司 2022-07-15 — — CN disclosed
US-20220185814-A1 SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2022-06-16 — — US disclosed
US-11168087-B2 Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2021-11-09 — — US disclosed
EP-3452481-A1 SUBSTITUTED IMIDAZO[1,2-b Lysosomal Therapeutics Inc. (US) 2019-03-13 — — EP disclosed
CN-109311902-A Substituted imidazo [1,2-b] pyridazine, substituted imidazo [1,5-b] pyridazine, related compound and their purposes in treatment medical disorder 溶酶体治疗股份有限公司 2019-02-05 — — CN disclosed
US-9868742-B2 Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b] pyridazines, related compounds, and their use in the treatment of medical disorders LYSOSOMAL THERAPEUTICS INC. (US) 2018-01-16 — — US disclosed
US-20170355702-A1 SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b] PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2017-12-14 — — US disclosed
WO-2017192930-A1 SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. (US) 2017-11-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355702-A1 SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b] PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GBA2, GALC GABRG2 841/4885GABRB3 1090/4885GABRA5 203/4885
US-11168087-B2 Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders GBA1, GBA2, GALC GABRG2 841/4885GABRB3 1090/4885GABRA5 203/4885
US-11878979-B2 Substituted imidazo[1,2-b]pyridazines, substituted imidazo[1,5-b]pyridazines, related compounds, and their use in the treatment of medical disorders GBA1, GBA2, GALC GABRG2 841/4885GABRB3 1090/4885GABRA5 203/4885
US-20220185814-A1 SUBSTITUTED IMIDAZO[1,2-b]PYRIDAZINES, SUBSTITUTED IMIDAZO[1,5-b]PYRIDAZINES, RELATED COMPOUNDS, AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GBA2, GALC GABRG2 841/4885GABRB3 1090/4885GABRA5 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback